Printer Friendly

Endpoint management, high-performance hardware support demanding hospital applications.

M2 EQUITYBITES-October 30, 2017-Endpoint management, high-performance hardware support demanding hospital applications

(C)2017 M2 COMMUNICATIONS http://www.m2.com

IGEL, a world provider of endpoint management software for the secure enterprise, and Advantech, a provider of medical computing solutions, have announced an ongoing development and technology partnership, the companies said.

The solution combines Advantech's hardware expertise and IGEL's software know-how to enable unique endpoint management capabilities especially designed for the healthcare sector.

Advantech's POC endpoints can be easily and remotely managed using the IGEL Universal Management Suite(TM) (UMS) software. This means that frequent settings can be easily predefined and assigned to individual devices or entire device groups using just a few mouse clicks.

Regular firmware updates can be distributed over the network in a simple, automated or timed manner. For a wide range of applications, IGEL's OS supports seamless access to a variety of virtualized and cloud-based IT infrastructure from Citrix, VMware and Microsoft. As a read-only operating system, the IGEL OS also securely protects sensitive data.

IGEL delivers powerful unified endpoint management software that is revolutionary in its simplicity and purpose-built for the enterprise. The company's world-leading software products include the IGEL OS(TM), Universal Desktop Converter(TM) (UDC), IGEL Cloud Gateway(TM) (ICG), IGEL UD Pocket(TM) (UDP) and Universal Management Suite(TM) (UMS). For more information on IGEL, visit www.igel.com.

Founded in 1983, Advantech is a provider of providing trusted, innovative products, services, and solutions. Advantech offers comprehensive system integration, hardware, software, customer-centric design services, embedded systems, automation products, and global logistics support.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2017 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Date:Oct 30, 2017
Words:270
Previous Article:Mereo BioPharma to License AstraZeneca Drug, with Option to Buy.
Next Article:Knowles inks agreement to divest timing device business.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters